US Top Rating Updates on 10/26: ABT, RBLX, REGN, WHR and More

Mizuho analyst Anthony Petrone initiated coverage of $Abbott Laboratories (ABT.US)$ with a Neutral rating and $105 price target. The analyst says the Neutral rating balances the benefits of the company's "solid" positioning in several of the fastest growing medical technology markets and "fortress" balance sheet against COVID testing and infant formula recall/relaunch headwinds.

Piper Sandler analyst Thomas Champion initiated coverage of $Roblox (RBLX.US)$ with an Overweight rating and $54 price target. Roblox is a "unique asset at the intersection of gaming, social, and the Metaverse," Champion tells investors in a research note. The analyst sees a large global user opportunity for the company and monetization upside versus peers.

Deutsche Bank analyst George Hill upgraded $Humana (HUM.US)$ to Buy from Hold with a price target of $576, up from $514. The analyst says six regional independent Medicare Advantage brokers confirmed to him the solidifying of Humana's leading position in Medicare Advantage, and the rising challenges facing many of its competitors.